ClinicalTrials.gg
Drug

Revumenib clinical trials

Also written SNDX-5613.

studies test it
26
open now
20
in phase 3
3
first study started
2016

How each study uses revumenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the revumenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
15 Nov 2024 · REVUFORJ · NDA 218944 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Revumenib
24
Menin-Mixed Lineage Leukemia Protein-Protein Interaction Inhibitor SNDX-5613
6
Menin-MLL Inhibitor SNDX-5613
6
Menin-MLL Interaction Inhibitor SNDX-5613
6

Brand

Revuforj
1

Development codes

SNDX-5613
17

Studies by the year they started

26 studies that test it; most in 2026 (10)

Studies that test revumenib, by start year
YearStudies
20161
20191
20222
20231
20249
20252
202610

By phase

A phase 1/2 study counts in both.

Phase 1
17
Phase 2
13
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 6 · Other 20

Syndax Pharmaceuticals (6) · M.D. Anderson Cancer Center (5) · Children's Oncology Group (2) · UNC Lineberger Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1) · John Mascarenhas (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · Center for International Blood and Marrow Transplant Research (1)

Often tested with

Tested in the same studies.

Venetoclax (3) · Azacitidine (2) · Cytarabine (2) · Daunorubicin (2) · Antineoplastic Agents (1) · Blinatumomab (1) · Mezigdomide (1) · Decitabine and cedazuridine drug combination (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6

Studies that test revumenib.

Studies

Open first, then newest update. How each study uses revumenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 26

See all 26 studies that test revumenib →

Given beside what is tested · 1 — revumenib is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call revumenib · ClinicalTrials.gg INT002034

  • MeSH (NLM) C000728983revumenibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) LZ0M43NNF2REVUMENIBConfirmed FDA, NLM
  • NCI Thesaurus C165776RevumenibOne source FDA

Also registered as revumenib citrate (UNII YL4RYN734D) and revumenib sesquifumarate (UNII 75HI05N8HS).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.